NASDAQ:IBIO iBio Q2 2026 Earnings Report $1.64 -0.02 (-0.91%) As of 03:45 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast iBio EPS ResultsActual EPS-$0.09Consensus EPS -$0.08Beat/MissMissed by -$0.01One Year Ago EPSN/AiBio Revenue ResultsActual RevenueN/AExpected Revenue$0.10 millionBeat/MissN/AYoY Revenue GrowthN/AiBio Announcement DetailsQuarterQ2 2026Date2/10/2026TimeAfter Market ClosesConference Call DateTuesday, February 10, 2026Conference Call Time4:00PM ETUpcoming EarningsiBio's Q4 2026 earnings is estimated for Friday, September 4, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) iBio Earnings HeadlinesiBio, Inc. (NASDAQ:IBIO) Receives Average Recommendation of "Buy" from AnalystsJune 20, 2026 | americanbankingnews.comCould iBio (IBIO) Be an Underrated Obesity Stock?June 11, 2026 | insidermonkey.comFour winners over 400%. Here's #5CFA and CMT analyst Garrett Goggin called G2 Goldfields before it rose 1,023%, Reunion Gold before 538%, Highlander Silver before 741%, and Orogen Royalty before 416%. He also publicly predicted Newmont's 126% gain in 2025. Now Goggin says the 1974 petrodollar agreement between Washington and Riyadh has quietly expired, central banks are buying gold at the fastest pace since 1950, and a major monetary shift is underway. He has identified four specific positions - plus two bonus opportunities for readers.June 24 at 1:00 AM | Golden Portfolio (Ad)5 Under-the-Radar AI Stocks to Buy in 2026June 11, 2026 | insidermonkey.comiBio to Participate in Upcoming Healthcare Investor ConferencesJune 2, 2026 | globenewswire.comiBio, Inc.: iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with ObesityJune 2, 2026 | finanznachrichten.deSee More iBio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like iBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on iBio and other key companies, straight to your email. Email Address About iBioiBio (NASDAQ:IBIO), a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.View iBio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why KB Home Could Reward Patient Investors LaterWhy nVent Could Be a Long-Term AI Infrastructure WinnerChevron’s Microsoft Deal Turns Natural Gas Into an AI TradeMicron’s Sudden Plunge May Be an AI Buying ChanceMarathon Petroleum Is Back, But Cycles Still MatterLiquid Gold: The AI Cooling Retrofit TradeCopa Holdings May Be the Airline Stock Built to Break Out Upcoming Earnings NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)ASML (7/15/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
